Biogen delivered a quarterly earnings beat on Wednesday, powered by strong demand for its rare-disease treatments and growing sales of its Alzheimer's drug Leqembi. But the good news came with a catch: the company also trimmed its 2026 profit outlook, citing acquisition-related charges tied largely to its $5.6 billion purchase of Apellis Pharmaceuticals.
The biotech firm reported revenue of $2.74 billion for the second quarter, ahead of the $2.46 billion analysts had expected, according to Reuters. Adjusted earnings came in at $3.60 per share, well above the $2.95 consensus estimate. The results show that Biogen can still grow beyond its aging multiple sclerosis franchise, which has faced generic competition in recent years.
What drove the beat
Two areas stood out in Biogen's quarter. First, demand for its rare-disease medicines remained strong. These drugs, which treat conditions like spinal muscular atrophy and hemophilia, have become a key growth driver as Biogen works to diversify its revenue base. Second, Leqembi, the Alzheimer's treatment it developed with Eisai, continued to ramp up. Sales of the drug, which received full U.S. approval last year, are climbing as more patients gain access and insurers expand coverage.
The rare-disease and Leqembi momentum helped offset ongoing pressure in Biogen's multiple sclerosis portfolio, where cheaper generics have eroded market share. The company has been investing in newer therapies to replace that lost revenue, and the latest quarter suggests that strategy is starting to pay off.
The Apellis deal takes a bite
But the quarter also revealed a significant drag from Biogen's recent acquisition spree. The company recorded an 85-cent-per-share charge related to its $5.6 billion purchase of Apellis, a deal that closed earlier this year. Apellis brings a promising eye drug for geographic atrophy, a leading cause of blindness, but integrating the acquisition comes with upfront costs that are now weighing on near-term profit forecasts.
As a result, Biogen trimmed its 2026 profit outlook. The company now expects adjusted earnings in 2026 to come in below its previous guidance, though it did not provide a specific new range. The move echoes a pattern seen across the biotech sector, where companies often lower long-term profit targets after large acquisitions as they absorb integration expenses and adjust for dilution. For context, Boston Scientific recently cut its 2026 profit forecast after a slowdown in demand for its Watchman device, showing that even strong operators face headwinds when growth drivers shift.
What it means for investors
For everyday investors, Biogen's report is a mixed bag. The earnings beat shows the company's core business is performing well, and the rare-disease and Leqembi growth stories remain intact. But the lowered 2026 outlook is a reminder that big acquisitions can create short-term pain even if they make strategic sense over the long haul.
Biogen's situation is not unique. Many companies that make large bolt-on acquisitions see their profit forecasts take a hit in the first year or two as they absorb costs. The key question for investors is whether the Apellis deal will eventually deliver the returns Biogen expects. The eye drug market is large and growing, but competition from rivals like Humana and other players in the ophthalmology space could limit upside.
Investors should also watch how Biogen manages its balance sheet. The Apellis deal added debt, and higher interest expenses could further pressure earnings if rates stay elevated. On the positive side, Biogen's strong cash flow from its rare-disease drugs gives it some cushion to absorb these costs without needing to cut research or marketing spending.
The broader market context matters too. Biotech stocks have been volatile this year as investors weigh interest rate expectations and drug pricing policy changes. Generac's strong quarter shows that demand for certain growth areas remains robust, but biotech companies face unique regulatory and reimbursement risks that can make their outlooks less predictable.
What to watch next
Biogen's next catalyst will likely be updates on Leqembi's commercial rollout. The drug is still in early stages of adoption, and any news on expanded Medicare coverage or new clinical data could move the stock. The company also has a pipeline of experimental treatments for rare diseases and neurology that could provide future growth.
For now, Biogen's message is clear: the business is growing, but the Apellis deal will take time to pay off. Investors who focus on the long-term potential of the company's rare-disease and Alzheimer's franchises may see the lowered 2026 outlook as a temporary bump. Those with a shorter time horizon might prefer to wait until the integration costs are behind the company.
As always, it's important to remember that past performance and earnings beats don't guarantee future results. Biogen's story is still unfolding, and the next few quarters will show whether the Apellis bet was worth the price.
